Article thumbnail

Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen

By Anthony Kong, Daniel Rea, Samreen Ahmed, J Thaddeus Beck, Rafael López López, Laura Biganzoli, Anne C Armstrong, Massimo Aglietta, Emilio Alba, Mario Campone, Shu-Fang Hsu Schmitz, Caroline Lefebvre, Mikhail Akimov and Soo-Chin Lee
Topics: AUY922; HER2; HSP90 inhibitor; breast cancer; trastuzumab
Publisher: 'Impact Journals, LLC'
Year: 2016
DOI identifier: 10.18632/oncotarget.8974
OAI identifier: oai:iris.unito.it:2318/1579732

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.